Featured Research

from universities, journals, and other organizations

Novel agent set for unique clinical test in inflammatory breast cancer

Date:
December 10, 2013
Source:
Thomas Jefferson University
Summary:
A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer.

A drug now used to treat a type of lymphoma has shown surprising benefit in preclinical studies of inflammatory breast cancer, according to a researcher at Thomas Jefferson University's Kimmel Cancer Center.

The finding, published online this month in the Journal of Experimental Therapeutics and Oncology, has led to development of a phase 1/2 clinical trial at Kimmel Cancer Center to test the agent, Romidepsin (Istodax™), in combination with nab-paclitaxel (Abraxane™) chemotherapy for advanced inflammatory breast cancer (IBC).

"Because this kind of breast cancer is very difficult to treat, we hope this new combination of anticancer agents will change the outcome of this aggressive disease," says the study's senior investigator, Massimo Cristofanilli, M.D., F.A.C.P., Professor of Medical Oncology and Director of the Jefferson Breast Care Center.

The study was conducted in collaboration with the lead author, Fredika Robertson, Ph.D., at The University of Texas M. D. Anderson Cancer Center, and was supported by a Promise Grant from the Susan G Komen Foundation awarded to Drs. Cristofanilli and Robertson in 2008.

Inflammatory breast cancer (IBC) is the most metastatic variant of locally advanced breast cancer, Dr. Cristofanilli says. Although it accounts for between 2-5 percent of all breast cancers in the United States -- and 13 percent of breast cancers globally -- it is responsible for a disproportionate number of deaths from breast cancer, he says.

One of the reasons for the lethality of inflammatory breast cancer is that early in the disease onset it produces emboli -- small balls of cancer cells -- which spread through the lymph system causing the typical breast swelling. These aggregates of cancer cells are resistant to chemotherapy, radiation, and are believed to be responsible for rapid metastasis, Dr. Cristofanilli says.

Experiments in laboratory cells and in mice models of inflammatory breast cancer demonstrates that Romidepsin is able to break the bonds that bind the cancer cells together, which then allows chemotherapy to effectively target single cancer cells, he says.

Romidepsin is a histone deacetylase (HDAC) inhibitor, a new class of drugs that regulates gene transcription in a unique way.

This study tested two other HDAC inhibitors, but found Romidepsin offered the best results. The agent was approved for use to treat cutaneous T-cell lymphoma in 2009. It is also undergoing clinical trials for use in other lymphomas.

"This study is a nice example of a transition from the laboratory to the clinic," says Dr. Cristofanilli. "Our laboratory work suggested it might be helpful to treat inflammatory breast cancer, and now we are about to open a clinical trial to test that very promising possibility."


Story Source:

The above story is based on materials provided by Thomas Jefferson University. Note: Materials may be edited for content and length.


Journal Reference:

  1. F.M. Robertson et al. The class I HDAC inhibitor Romidepsin targets inflammatory breast cancer tumor emboli and synergizes with paclitaxel to inhibit metastasis. JETO, 10:219-233, 2013

Cite This Page:

Thomas Jefferson University. "Novel agent set for unique clinical test in inflammatory breast cancer." ScienceDaily. ScienceDaily, 10 December 2013. <www.sciencedaily.com/releases/2013/12/131210163533.htm>.
Thomas Jefferson University. (2013, December 10). Novel agent set for unique clinical test in inflammatory breast cancer. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2013/12/131210163533.htm
Thomas Jefferson University. "Novel agent set for unique clinical test in inflammatory breast cancer." ScienceDaily. www.sciencedaily.com/releases/2013/12/131210163533.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com
How The 'Angelina Jolie Effect' Increased Cancer Screenings

How The 'Angelina Jolie Effect' Increased Cancer Screenings

Newsy (Sep. 19, 2014) Angelina's Jolie's decision to undergo a preventative mastectomy in 2013 inspired many women to seek early screenings for the disease. Video provided by Newsy
Powered by NewsLook.com
The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins